US 2026/0097115 A1 · IMMUNOGENIC COMPOSITIONS AND USE THEREOF

Abstract

Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.

Claims57

Dependent claims

An immunogenic composition comprising one or more peptides, wherein the one or more peptides are:

a. capable of binding to Major Histocompatibility Complex (MHC) class II, wherein the MHC class II is Human Leukocyte Antigen class II (HLA-II), and
b. derived from translation products of SARS-CoV-2.

A method of identifying immunogenic peptides comprising:

a. lysing cells having a potential to express the immunogenic peptides of interest with a lysis buffer comprising a cell membrane disrupting detergent, wherein the cell membrane disrupting agent is a nonylphenol ethoxylate surfactant;
b. enzymatic shearing of nucleic acids in the lysed cells, wherein the nucleic acids in the lysed cells are enzymatically sheared using an endonuclease from Serratia marcescens and MgCl2;
c. isolating HLA-II from the lysed cells, wherein the HLA-II is in complex with one or more peptides from the lysed cells, wherein isolating HLA-II comprises immunoprecipitation of the HLA-II complex with an anti-HLA-II antibody;
and
d. determining sequences of the one or more peptides in complex with the HLA-II from (c), wherein (d) is performed by liquid chromatography tandem mass spectrometry analysis.

2 more elements

Dependencies are inferred from the claim text.

Immunogenic compositions and use thereof

Life of this patent

Immunogenic compositions and use thereof

Life of this patent

Abstract

Claims57